(Q54342129)

English

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

scientific article

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

title

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

1 reference

John M Lambert

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

Ravi V J Chari

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

language of work or name

English

0 references

publication date

10 July 2014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

published in

Journal of Medicinal Chemistry

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

volume

57

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

issue

16

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

page(s)

6949-6964

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

cites work

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1158/0008-5472.CAN-08-1776

Identifiers

DOI

10.1021/JM500766W

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

PubMed publication ID

24967516

1 reference

stated in

Europe PubMed Central

PubMed publication ID

24967516

retrieved

28 May 2018

reference URL

http://europepmc.org/abstract/MED/24967516

ResearchGate publication ID

263430254

0 references

(Q54342129)

Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)